期刊文献+

通心络预给药2小时对猪急性心肌梗死再灌注后心肌微血管内皮结构完整和无再流的保护作用 被引量:20

Effects of tongxinluo on mini-swine vascular endothelial integrity and myocardial no-reflow in early reperfusion of acute myocardial infarction
原文传递
导出
摘要 目的评价冠脉再通前2h给予不同剂量通心络对猪急性心肌梗死(AMI)缺血再灌注后心肌微血管结构完整和无再流变化的疗效。方法中华小型猪40只,分成假手术组、AMI对照组、通心络治疗组:小剂量(0.1g/kg)、中剂量(0.2g/kg)和大剂量(0.4g/kg),每组8只。冠状动脉前降支阻断1.5h,再灌注3h建立AMI缺血再灌注动物模型。各通心络治疗组于AMI缺血再灌注前2h行灌胃给药。测定并比较各组再灌注后3h正常区、再灌注区、无再流区心肌组织中血管内皮钙黏连蛋白、8连环蛋白、基质金属蛋白酶(MMP)-2和9水平变化。于AMI1.5h和再灌注3h行心肌声学造影(MCE),测定并比较心肌无再流面积变化。结果(1)与正常区相比,对照组再灌注区和无再流区心肌组织中血管内皮钙黏连蛋白和B连环蛋白水平均显著降低,而MMP-2、9水平均显著升高(P均〈0.05),且无再流区变化更显著(P均〈0.05);(2)大剂量通心络能够显著升高再灌注区和无再流区血管内皮钙黏连蛋白和[(22.2±3.2)%比(32.0±3.9)%和(14.5±2.8)%比(28.3±2.2)%],B连环蛋白[(20.5±3.5)%比(27.3±2.9)%和(13.3±2.1)%比(20.6±2.4)%],同时显著降低再灌注区和无再流区MMP-2[(48.3±4.1)%比(29.4±3.5)%和(57.3±4.3)%比(38.2±4.0)%l,MMP-9[(55.6±4.0)%比(34.3±3.5)%和(62.4±4.8)%比(44.4±4.1)%,P均〈0.05];(3)大剂量通心络能够显著缩小再灌注后3h心肌无再流区面积[(6.6±1.7)cm^2比(4.8±1.5)cm^2,P〈0.05];和心肌无再流范围[(90.8±3.8)%比(71.4±4.1)%,P〈0.05]。结论AMI缺血再灌注前2h预给予大剂量通心络对心肌微血管内皮结构完整和心肌无再流有明确保护作用,为通心络的临床应用提供了实验依据。 Objective To assess the effects of tongxinluo on vascular endothelial integrity and myocardial no-reflow in early reperfusion of acute myocardial infarction. Methods Forty mini-swines were divided into five groups randomly, sham group, control group, low dose (0. 1 g/kg), medium dose (0. 2 g/ kg) and high dose (0. 4 g/kg) groups of Tongxinluo. It was administered at 2 hours pre-reperfusion. Animals except in sham group were subjected to 1.5 hour of coronary occlusion followed by 3 hours of reperfusion. Content of VE-cadherin, 13-catenin, matrix metalloproteinase (MMP) -2 and 9 in myocardium were evaluated; no-reflow area was examined with myocardial contrast echocardiography (MCE) at 1.5 hour of AMI and 3 hours of reperfusion. Results ( 1 ) Compared with that of normal myocardium, content of VE- cadherin and 15-catenin decreased in reperfusion and no-reflow myocardium while MMP-2 and 9 increased significantly ( all P 〈 0. 05 ) ; ( 2 ) Compared with that of control group, a high dose of Tongxinluo could increase significantly the content of VE-eadherin in both reperfusion and no-reflow myocardium, (22. 2 ± 3.2)% vs (32.0±3.9)% and (14.5 ±2.8)% vs (28.3 ±2.2)% respectively, 13-catenin, (20.5±3.5)% vs (27.3 ±2.9)% and (13.3 ±2. 1)% vs (20.6 ±2.4)% ,while reduce MMP-2, (48.3 ± 4.1)% vs (29.4±3.5)% and (57.3 ±4.3)% vs (38.2±4.0)% respectively, MMP-9, (55.6± 4.0)% vs (34.3±3.5)% and (62.4±4.8)% vs (44.4±4.1)%,allP〈0.05; (3) Compared with that of control group, a high dose of Tongxinluo could reduce significantly both no-reflow area, (6. 6 ± 1.7 ) cm2vs (4.7±1.5)em2, P〈0.05, and percentage(90.8±3.8)% vs (71.4±4.1)%, P〈0.05, at3 hours of reperfusion. Conclusion A high dose of tongxinluo could effectively maintain the integrity of vascular endothelium and attenuate no-reflow area in early reperfusion of acute myocardial infarction.
出处 《中华医学杂志》 CAS CSCD 北大核心 2009年第20期1421-1425,共5页 National Medical Journal of China
基金 国家重点科技研究发展计划基金(2005CB523303)
关键词 心肌梗死 内皮 血管 基质金属蛋白酶 通心络 Myocardial infarction Endothelium, vascular Matrix metalloproteinases Tongxinluo
  • 相关文献

参考文献15

  • 1Kelly RV, Cohen MG, Runge MS, et al. The no-reflow phenomenon in coronary arteries. J Thromb Haemost, 2004, 2: 1903 -1907.
  • 2杨跃进,赵京林.应重视急性心肌梗死再灌注后无再流的防治[J].中华医学杂志,2005,85(31):2169-2170. 被引量:5
  • 3赵京林,杨跃进,尤士杰,荆志成,吴永建,杨伟宪,陈纪林,高润霖,陈在嘉.通心络对猪急性心肌梗死再灌注后内皮素-1的影响[J].中国中西医结合杂志,2005,25(10):902-906. 被引量:11
  • 4Lindsey M, Wedin K, Michael D, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation, 2001, 103 : 2181-2187.
  • 5杨跃进,赵京林,荆志成,吴永健,尤士杰,杨伟宪,孟亮,田毅,陈纪林,高润霖,陈在嘉.中药通心络对猪急性心肌梗死再灌注后无再流的影响[J].中华医学杂志,2005,85(13):883-888. 被引量:34
  • 6Peter AV, Kanyan X, Kathleen M, et al. VE-cadherin: adhesion at arm's length. Am J Physiol Cell Physiol, 2004, 286:987-997.
  • 7Dejana E, Spagnuolo R, Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thmmb Haemost, 2001, 86 : 308-315.
  • 8Zhao X, Alexander JS, Zhang S, et al. Redox regulation of endothelial barrier integrity. Am J Physiol Lung Cell Mol Physiol, 2001, 281 : L879-L886.
  • 9Barandon L, Couffinhal T, Ezam J, et al. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation, 2003, 108 : 2282-2289.
  • 10Etoh T, Jofs C, Deschamps AI, et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol Heart Circ Physiol, 2001, 281 : 987-994.

二级参考文献61

  • 1赵明中,高承梅,张宇洋.通心络胶囊对实验性心肌缺血再灌注损伤保护作用的实验研究[J].中国中医基础医学杂志,2000,6(1):36-38. 被引量:50
  • 2赵京林,杨跃进,尤士杰,荆志成,吴永健,杨伟宪,孟亮,田毅,陈纪林,高润霖,陈在嘉.地尔硫卓对猪急性心肌梗死再灌注后无再流的影响[J].中华医学杂志,2005,85(10):679-683. 被引量:7
  • 3杨跃进,赵京林,荆志成,吴永健,尤士杰,杨伟宪,孟亮,田毅,陈纪林,高润霖,陈在嘉.中药通心络对猪急性心肌梗死再灌注后无再流的影响[J].中华医学杂志,2005,85(13):883-888. 被引量:34
  • 4Ito H,Maruyama A,Iwakura K,et al.Clinical implications of the ‘no-reflow' phenomenon:a predictor of complications and left ventricular remodeling in perfused anterior wall myocardial infarction.Circulation 1996; 93:223-228.
  • 5Gersh BJ.Optimal management of acute myocardial infarction at the down of the next millennium.Am Heart J 1999; 138 (2Pt2):188-202.
  • 6Piana RN,Paik GY,Moscucci M,et al.Incidence and treat ment of "no-reflow" after percutaneous coronary intervention.1994;89:2514.
  • 7Ito H,Tomooka T,Sakai N,et al.Lack of myocardial perfusion immediately after successful thrombolysis:a predictor of poor recovery of left ventricular function in anterior myocardial infarction.Circulation 1992; 85:1699-1705.
  • 8Abbo KM,Dooris M,Glaziar S.Features and outcome of noreflow after percutaneous coronary intervention.Am J Cardiol 1995 ;75:778-82.
  • 9Morshima J.Long term prognostic impact of angiographic noreflow phenomenon in patients treated with angioplasty for acute myocardial infarction possible involvement of left ventricular remodeling.Circulation 1999; 100(Suppl 1):451-456.
  • 10Eeckhout E,Kern MJ.The coronary no-reflow phenomenon:a review of mechanism and therapies.Eur Heart J 2001; 22:729-739.

共引文献68

同被引文献217

引证文献20

二级引证文献219

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部